Leerink Partners analyst Mani Foroohar has maintained their neutral stance on RCKT stock, giving a Hold rating on August 20.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Mani Foroohar has given his Hold rating due to a combination of factors surrounding Rocket Pharmaceuticals’ recent developments. The FDA has lifted the clinical hold on their pivotal Phase 2 study for RP-A501 in Danon disease, which was initially paused due to a serious adverse event. This event involved a capillary leak syndrome that resulted in a patient’s death, prompting the need for a revised study protocol.
While the resumption of the study at a lower dose is seen as a positive step, there are still uncertainties regarding the efficacy at this new dosage level and the impact of the updated immunomodulatory regimen. Additionally, questions remain about whether the FDA will require further protocol amendments, including potentially expanding the number of patients in the study. These factors contribute to the Hold rating, as further data and regulatory interactions in 2026 will be crucial in determining the future trajectory of the RP-A501 program.
Foroohar covers the Healthcare sector, focusing on stocks such as RegenXBio, Moderna, and Arrowhead Pharmaceuticals. According to TipRanks, Foroohar has an average return of -6.6% and a 42.92% success rate on recommended stocks.